Ingvild Lane
Internal Medicine · Sacramento, CANPI 1831171719
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 681 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 681 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Pfizer$1K
- Novo Nordisk$894
- Lilly USA, LLC$885
- AbbVie$865
- Boehringer Ingelheim$831
- plus $6K from 53 others
What the payments were for
- Food & beverage$11,986100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$12,016 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $125,638 |
| EliquisApixaban | 108 | $118,428 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $71,631 |
| JardianceEmpagliflozin | 43 | $60,820 |
| MounjaroTirzepatide | 45 | $60,609 |
| XareltoRivaroxaban | 43 | $54,270 |
| FarxigaDapagliflozin Propanediol | 33 | $28,246 |
| MyrbetriqMirabegron | 37 | $20,910 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $20,844 |
| TrulicityDulaglutide | 15 | $15,943 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,215 |
| GemtesaVibegron | 18 | $9,548 |
| Levothyroxine Sodium | 545 | $8,523 |
| BelsomraSuvorexant | 18 | $7,827 |
| Azelastine Hcl | 187 | $5,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $894 | $125,638103 claims |
| PfizerEliquis | $1,112 | $118,428108 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $275 | $99,876138 claims |
| Lilly USA, LLCMounjaro, Trulicity | $885 | $76,55260 claims |
| Boehringer IngelheimJardiance | $831 | $60,82043 claims |
| Johnson & JohnsonXarelto | $662 | $54,27043 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $1,233 | $34,05947 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $20,91037 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $124 | $9,54818 claims |
| MerckBelsomra | $538 | $7,82718 claims |
| AbbVieSynthroid | $865 | $4,86654 claims |
| Mylan Inc.Atorvastatin Calcium | $34 | $4,656434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Sacramento
- Christian SandrockSacramento$2.1M
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.